**Supplementary Table S2. Phase I patient disposition**

| | Group I | | | | Group II | | | | |
|---|---|---|---|---|---|---|---|---|---|
| **Parameter, *n* (%)** | **Nintedanib, 100 mg bid** | **Nintedanib, 150 mg bid** | **Nintedanib, 200 mg bid** | **Total** | **Nintedanib, 50 mg bid** | **Nintedanib, 100 mg bid** | **Nintedanib, 150 mg bid** | **Nintedanib, 200 mg bid** | **Total** |
| Discontinued from trial medication | 6 (100) | 3 (100) | 4 (100) | 13 (100) | 3 (100) | 4 (100) | 4 (100) | 8 (100) | 19 (100) |
| Progressive disease | 2 (33.3) | 1 (33.3) | 1 (25.0) | 4 (30.8) | 0 | 2 (50.0) | 1 (25.0) | 1 (12.5) | 4 (21.1) |
| AEs | 4 (66.7) | 2 (66.7) | 3 (75.0) | 9 (69.2) | 3 (100) | 2 (50) | 2 (50) | 7 (87.5) | 14 (73.7) |
| DLT | 2 (33.3) | 1 (33.3) | 0 | 3 (23.1) | 0 | 1 (25.0) | 0 | 2 (25.0) | 3 (15.8) |
| Other AE | 2 (33.3) | 1 (33.3) | 3 (75.0) | 6 (46.2) | 3 (100) | 1 (25.0) | 2 (50.0) | 5 (62.5) | 11 (57.9) |
| Non-compliant with protocol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Refused to continue taking trial medication | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 (25.0) | 0 | 1 (5.3) |

Abbreviations: AE, adverse events; DLT, dose-limiting toxicity